0.64
-0.006(-0.93%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.64 |
| Day High | 0.66 |
| Day Low | 0.63 |
| 52-Week High | 1.99 |
| 52-Week Low | 0.45 |
| Volume | 114,008 |
| Average Volume | 177,241 |
| Market Cap | 48.07M |
| PE | -1 |
| EPS | -0.64 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 1.04 |
| Change | -0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $54.86 as of June 01, 2025 at a share price of $0.638. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $21.72 as of June 01, 2025 at a share price of $0.638.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
May 12, 2025 8:05 PM GMT
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise S
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE),
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire Inc.
May 05, 2025 2:00 PM GMT
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment o